
Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.
Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 11, 11, 12, 1, 17, 10 and 1 respectively.
Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.
Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 11, 11, 12, 1, 17, 10 and 1 respectively.
Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
119 Pages
- Introduction
- Global Markets Direct Report Coverage
- Ankylosing Spondylitis (Bekhterev's Disease) – Overview
- Ankylosing Spondylitis (Bekhterev's Disease) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Ankylosing Spondylitis (Bekhterev's Disease) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ankylosing Spondylitis (Bekhterev's Disease) – Companies Involved in Therapeutics Development
- 3SBio Inc
- AbbVie Inc
- Akeso Inc
- AstraZeneca Plc
- Avesthagen Ltd
- Beijing Eastern Biotech Co Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biogen Inc
- Bioviz Technologies Pvt Ltd
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Celltrion Inc
- Clover Biopharmaceuticals Ltd
- DNX Biopharmaceuticals Inc
- Dyadic International Inc
- Eli Lilly and Co
- Enzene Biosciences Ltd
- Foshan Rexie Biotechnology Co Ltd
- FunPep Co Ltd
- Huabo Biopharm (Shanghai) Co Ltd
- Hualan Biological Engineering Inc
- Iltoo Pharma
- Immunwork Inc
- Izana Bioscience Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Lynk Pharmaceutical Hangzhou Co Ltd
- Mabpharm Ltd
- MoonLake Immunotherapeutics
- Mycenax Biotech Inc
- NeuClone Pty Ltd
- Nimbus Therapeutics LLC
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- Novartis AG
- Outlook Therapeutics Inc
- Pharmapraxis
- PKU V-Ming (Hefei) Biologics Co Ltd
- Qilu Pharmaceutical Co Ltd
- Sandoz International GmbH
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Siam Bioscience Co Ltd
- SinoCelltech Group Ltd
- siRNAgen Therapeutics Corp
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Tianjin Hemay Pharmaceutical Co Ltd
- UCB SA
- Valin Technologies Ltd
- Wuhan Institute of Biological Products Co Ltd
- XinThera Inc
- Zhejiang Yatai Pharmaceutical Co Ltd
- Ankylosing Spondylitis (Bekhterev's Disease) – Drug Profiles
- adalimumab biosimilar – Drug Profile
- aldesleukin – Drug Profile
- Antisense RNAi Oligonucleotides for Autoimmune Disorders – Drug Profile
- BCD-180 – Drug Profile
- BI-730357 – Drug Profile
- bimekizumab – Drug Profile
- brodalumab – Drug Profile
- CC-99677 – Drug Profile
- celecoxib – Drug Profile
- certolizumab pegol biosimilar – Drug Profile
- CNTO-6785 – Drug Profile
- DNX-114 – Drug Profile
- DNX-514 – Drug Profile
- etanercept biosimilar – Drug Profile
- FPP-003 – Drug Profile
- golimumab biosimilar – Drug Profile
- gumokimab – Drug Profile
- HB-0017 – Drug Profile
- Hemay-005 – Drug Profile
- infliximab biosimilar – Drug Profile
- ivarmacitinib sulfate – Drug Profile
- ixekizumab – Drug Profile
- jaktinib hydrochloride – Drug Profile
- JS-005 – Drug Profile
- KFPH-018 – Drug Profile
- LNK-01001 – Drug Profile
- LQ-026 – Drug Profile
- LZM-012 – Drug Profile
- MK2 Backup – Drug Profile
- Monoclonal Antibody to Inhibit TNF alpha for Ankylosing Spondylitis, Psoriasis and Rheumatoid Arthritis – Drug Profile
- namilumab – Drug Profile
- NDI-031407 – Drug Profile
- netakimab – Drug Profile
- Proteins for Immunology and Metabolic Disorders – Drug Profile
- QX-002N – Drug Profile
- SCT-650A – Drug Profile
- secukinumab – Drug Profile
- secukinumab biosimilar – Drug Profile
- sonelokimab – Drug Profile
- SSGJ-608 – Drug Profile
- TE-2122 – Drug Profile
- TE-2158 – Drug Profile
- upadacitinib ER – Drug Profile
- ustekinumab biosimilar – Drug Profile
- Van-301 – Drug Profile
- vunakizumab – Drug Profile
- XIN-005404 – Drug Profile
- Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects
- Ankylosing Spondylitis (Bekhterev's Disease) – Discontinued Products
- Ankylosing Spondylitis (Bekhterev's Disease) – Product Development Milestones
- Featured News & Press Releases
- Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
- Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China
- Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
- Jul 20, 2022: Health Canada approves AbbVie's RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis
- Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
- May 02, 2022: FDA grants approval for AbbVie's Rinvoq to treat ankylosing spondylitis
- Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
- Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
- Dec 28, 2021: Akeso's IL-17A monoclonal antibody (Gumokimab) completion of patient enrollment in phase II clinical trial for the treatment of ankylosing spondylitis
- Dec 08, 2021: Xinkanghe XKH004 ankylosing spondylitis phase II clinical trial investigator meeting was successfully held
- Oct 07, 2021: AbbVie's RINVOQ (upadacitinib) met primary and all ranked secondary endpoints in phase 3 study in ankylosing spondylitis
- Jun 25, 2021: AbbVie provides update regarding RINVOQ (upadacitinib) in psoriatic arthritis and ankylosing spondylitis in the U.S.
- Feb 16, 2021: Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz (adalimumab)
- Jan 25, 2021: European Commission approves AbbVie's RINVOQ (Upadacitinib) for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis
- Dec 22, 2020: China IND application of recombinant anti-human IL-17A/F humanized monoclonal antibody injection for AS indication is accepted by CDE
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Companies, 2022 (Contd..3)
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Mechanism of Action, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by 3SBio Inc, 2022
- Table 14: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by AbbVie Inc, 2022
- Table 15: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Akeso Inc, 2022
- Table 16: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by AstraZeneca Plc, 2022
- Table 17: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Avesthagen Ltd, 2022
- Table 18: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Beijing Eastern Biotech Co Ltd, 2022
- Table 19: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Bio-Thera Solutions Ltd, 2022
- Table 20: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biocad, 2022
- Table 21: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biogen Inc, 2022
- Table 22: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Bioviz Technologies Pvt Ltd, 2022
- Table 23: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by BioXpress Therapeutics SA, 2022
- Table 24: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Boehringer Ingelheim International GmbH, 2022
- Table 25: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 26: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Celltrion Inc, 2022
- Table 27: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Clover Biopharmaceuticals Ltd, 2022
- Table 28: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by DNX Biopharmaceuticals Inc, 2022
- Table 29: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Dyadic International Inc, 2022
- Table 30: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Eli Lilly and Co, 2022
- Table 31: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Enzene Biosciences Ltd, 2022
- Table 32: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Foshan Rexie Biotechnology Co Ltd, 2022
- Table 33: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by FunPep Co Ltd, 2022
- Table 34: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
- Table 35: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Hualan Biological Engineering Inc, 2022
- Table 36: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Iltoo Pharma, 2022
- Table 37: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Immunwork Inc, 2022
- Table 38: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Izana Bioscience Ltd, 2022
- Table 39: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
- Table 40: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 41: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
- Table 42: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Johnson & Johnson, 2022
- Table 43: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
- Table 44: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Luye Pharma Group Ltd, 2022
- Table 45: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
- Table 46: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Mabpharm Ltd, 2022
- Table 47: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by MoonLake Immunotherapeutics, 2022
- Table 48: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Mycenax Biotech Inc, 2022
- Table 49: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by NeuClone Pty Ltd, 2022
- Table 50: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Nimbus Therapeutics LLC, 2022
- Table 51: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2022
- Table 52: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Novartis AG, 2022
- Table 53: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Outlook Therapeutics Inc, 2022
- Table 54: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Pharmapraxis, 2022
- Table 55: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by PKU V-Ming (Hefei) Biologics Co Ltd, 2022
- Table 56: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Table 57: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Sandoz International GmbH, 2022
- Table 58: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
- Table 59: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 60: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022
- Table 61: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Siam Bioscience Co Ltd, 2022
- Table 62: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by SinoCelltech Group Ltd, 2022
- Table 63: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by siRNAgen Therapeutics Corp, 2022
- Table 64: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
- Table 65: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
- Table 66: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by UCB SA, 2022
- Table 67: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Valin Technologies Ltd, 2022
- Table 68: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
- Table 69: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by XinThera Inc, 2022
- Table 70: Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
- Table 71: Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, 2022
- Table 72: Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, 2022 (Contd..1)
- Table 73: Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, 2022 (Contd..2)
- Table 74: Ankylosing Spondylitis (Bekhterev's Disease) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.